Healthcare Global Enterprises Limited has informed the Exchange regarding a press release dated May 19, 2026, titled Press release on Annual Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2026.
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
HCG reported strong FY26 results with full-year revenue growing 15% to Rs. 25,454 million, driven by resilient demand across medical, radiation, and surgical oncology modalities. Adjusted EBITDA rose 19% to Rs. 4,711 million with margins expanding 68 basis points to 18.5%. Q4 FY26 was particularly robust with adjusted PAT jumping 363% year-on-year to Rs. 341 million, benefiting from improved throughput and cost discipline. The company completed a Rs. 4,250 million rights issue during the year, strengthening its financial position to fund capacity expansion and technology investments. Management highlighted focus on next-generation oncology capabilities including precision medicine, molecular diagnostics, genomics, and robotics.
The results demonstrate consistent execution with strong margin expansion and profitability acceleration, supported by a successful capital raise. The stock should be viewed positively given the 15% revenue growth, 19% EBITDA growth, and significant PAT jump, signaling operational leverage across the network.